ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1601215
This article is part of the Research TopicTumor-Associated Macrophages and Tumor-Infiltrating Lymphocytes in the Tumor MicroenvironmentView all 5 articles
Progression to fibrosis and hepatocellular carcinoma in DEN CCl4 liver mice, is associated with macrophage and striking regulatory T cells infiltration
Provisionally accepted- 1Laboratory of Paediatric Hepatology and Cell Therapy, Institut de recherche expérimentale et clinique, Faculté de pharmacie et des sciences biomédicales, Université catholique de Louvain, Brussels, Belgium
- 2Plateforme d'imagerie IREC, Institut de Recherche Expérimentale et Clinique, Faculté de Pharmacie et des Sciences Biomédicales, Université Catholique de Louvain, Brussels, Belgium
- 3CytoFlux-IREC Flow Cytometry and Cell Sorting Platform, Institut de recherche expérimentale et clinique, Faculté de pharmacie et des sciences biomédicales, Université catholique de Louvain, Brussels, Belgium
- 4Genetics and Immune Cell Therapy Unit, LBBES Laboratory, Faculty of Sciences, Mohamed Premier University, Oujda, Morocco
- 5Faculté de médecine, Université libre de Bruxelles, Brussels, Belgium
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background & AimHepatocellular carcinoma (HCC) is a classic inflammation related cancer with most cases arising from chronic liver disease (CLD). This study investigates immune dysregulation that occurs during the progression of CLD to HCC by delineating changes in immune cell composition and distribution within the liver microenvironment.MethodsMice were injected with Diethylnitrosamine (DEN) at 4 weeks of age, followed by continuous tri-weekly injections of carbon tetrachloride (CCl4) for 6 and 21 weeks to induce liver fibrosis and HCC. Naïve and Phosphate-buffered saline (PBS) corn oil treated mice were used as controls. Immune cell profiling was performed using multiplex immunofluorescence and flow cytometry analyses.ResultsThe spatial analysis of immune cell populations in HCC reveals stable leukocytes overall, with notable increases in myeloid cells, particularly infiltrating macrophages (Inf mph). Indeed, Inf mph show a progressive enrichment from control to tumor, reaching a 5-fold and 10-fold increase in the invasive margin (IM) and surrounding non-tumor tissue (NTT) regions, respectively. T lymphocytes, especially CD4+ T cells but not CD8+ T cells, significantly expand, with CD4+ cells increasing up to 10-fold in the IM and NTT regions of HCC livers. Regulatory T cells (Tregs) population exhibits an extraordinary 125-fold and 80-fold surge in the IM and NTT regions, respectively. ConclusionsThe DEN-CCl4 induced HCC mouse model replicates key immunosuppressive features of human HCC, notably increased Tregs and macrophages, which provides a robust platform for testing immunotherapies. The prominence of immune cells in the IM region underscores its importance as a critical interface modulating tumor-immune interactions, while the elevated immune presence in the NTT region reflects broader immune dysregulation associated with advanced CLD, and potentially facilitating tumor progression.
Keywords: Liver, liver fibrosis, Hepatocellular Carcinoma, immune cells, Multiplex immunofluorescence, Flow Cytometry
Received: 27 Mar 2025; Accepted: 23 Jun 2025.
Copyright: © 2025 Ajith, Evraerts, Bouzin, Brusa, Merimi, Najar, Smets, Sokal and NAJIMI. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Mustapha NAJIMI, Laboratory of Paediatric Hepatology and Cell Therapy, Institut de recherche expérimentale et clinique, Faculté de pharmacie et des sciences biomédicales, Université catholique de Louvain, Brussels, 1200, Belgium
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.